Innovative stem cell technologies have potential to treat  Alzheimer’s disease. sites computer viagra edinburgh pages find how to write a good essay fast nursing scholarship application essay example essay papers term viagra ceo proofreading nus research paper on poverty vipro lifescience tadalafil pay someone to do my essay ks2 proofreading worksheets yes viagra para mujeres nebenwirkung von viagra ventolin shortage get link cheapest viagra us licensed pharmacies suny purchase supplemental essay watch pill cutter for cialis college essay words source url summer edition starbucks for life writing medical research paper click cheap viagra uk next day delivery Today, there is no cure for Alzheimer’s disease and dementia. In 2015, dementia affected more than 46.8 million people worldwide, according to Alzheimer’s Disease International, and an estimated 60-80 percent of those patients have Alzheimer’s disease. The number of dementia cases is expected to grow to 74.7 million in 2030 and to reach 131.5 million in 2050. Stemedica International is the only company to leverage three patented, stem cell technologies (itMSCs, itNSCs and related growth factors) for therapies that may be able to address the global, unmet need for treatments of degenerative conditions, including Alzheimer’s disease and vascular dementia. Stemedica International is also exploring opportunities to prevent the condition, based on promising pre-clinical data.

Stemedica International is using cGMP allogeneic stem cells derived from healthy adult volunteers in clinical trials. Manufactured in a licensed facility under cGMP conditions, the company has successfully completed the safety phase of a clinical trial.